Details for Patent: 7,895,059

Scope and Claims Analysis of U.S. Patent 7,895,059 (Central Pharmacy Controlled Distribution for GHB and Other Prescription Drugs)

U.S. Patent 7,895,059 covers a computerized, centralized distribution workflow in which an “exclusive central pharmacy” uses an “exclusive computer database” to screen prescribers and patients, detect abuse/diversion patterns, and controls whether shipment/dispensing occurs, including an option to route dispensing through another pharmacy under additional controls. The claims repeatedly anchor coverage to (i) exclusive central pharmacy control, (ii) mandatory use of the exclusive database, (iii) credential eligibility checks, (iv) patient education confirmation before first shipment, (v) database-driven abuse screening tied to patient/prescriber, (vi) mail/courier shipment only if not flagged, and (vii) periodic reporting to evaluate diversion. Multiple dependent claims narrow to gamma hydroxy butyrate (GHB) and to supply and operational control features (e.g., blocking shipment; authorizing another pharmacy; insurance/early-refill and lost/stolen flagging; limited duration supply).

Core claim scope: method claims for distribution/dispensing governance rather than composition of matter, formulation, or pricing. The “exclusive” and “required database use” elements are the main enforceability levers, and also the likely non-infringement attack surfaces.

What is U.S. Patent 7,895,059 protecting: computerized central pharmacy control of prescription drug distribution?

Answer: The patent protects computer-implemented methods that force all workflow decisions for a controlled prescription drug to be made through an exclusive central pharmacy system using an exclusive database for abuse/diversion analysis, with eligibility checks and shipment gating.

Claim architecture and repeated limitations (claims 1, 6, 9, 12, 13, 14 and their dependents)

Across the independent methods, the claims share a common sequence and set of requirements:

1. Receive prescription requests in a processor

   • Requests are received “only at the exclusive central pharmacy” (or “only at the central pharmacy” in several versions).
   • Requests come from authorized/allowed medical doctors/prescribers.

2. Prescription request content

   • Includes patient-identifying information
   • Identifies the prescription drug (in the general claims) or explicitly GHB (in the GHB claims)
   • Includes credentials of prescribers/authorized doctors

3. Exclusive database entry and mandatory use

   • Enter information into an “exclusive computer database associated with the exclusive central pharmacy”.
   • The use of the database is required for distribution, with all prescriptions processed only by the central pharmacy using only that database.

4. Prescriber credential eligibility checking

   • Check prescriber credentials via the processor to determine prescriber eligibility.

5. Patient education confirmation

   • Confirm with the patient that educational material has been received and/or read prior to shipping/providing (often specified as prior to first time).

6. Abuse/diversion checking against patient (and prescriber)

   • Check the database for potential abuse (general) or potential GHB abuse associated with the patient (GHB claims).
   • The general and dependent forms include variants like blocking shipment upon abuse association.

7. Conditional dispensing/shipment

   • Mail or courier the drug only if no potential abuse is found (or only if database is not indicative of potential abuse).

8. Receipt confirmation by patient

   • Confirm patient receipt of the drug.

9. Periodic reporting

   • Generate periodic reports via the exclusive database to evaluate diversion patterns.

How the claims differentiate “general prescription drug” vs “GHB”

• General claims (e.g., claim 1, claim 6, claim 14) cover “a prescription drug” with the same central-control and database screening concept.
• GHB-specific claims (e.g., claims 9, 12, 13) explicitly recite gamma hydroxy butyrate (GHB) and add GHB-specific framing, including GHB educational material and potential GHB abuse.

Manufacturing and supply chain coverage (claim 13)

Claim 13 adds a manufacturing step and tightens control of distribution upstream:

• Manufacturing GHB
• Providing manufactured GHB only to the exclusive central pharmacy
• Then executing the same centralized database screening and shipment gating.

This creates a distinct infringement pathway: systems that include upstream manufacturing-to-central-pharmacy restriction in addition to distribution workflow.

What are the independent claim limitations that define infringement risk and claim scope?

Answer: Infringement hinges on satisfying the “exclusive central pharmacy + exclusive database + all prescriptions processed using only that database + shipment/dispensing gated by database abuse screening + education confirmation + receipt confirmation + periodic diversion reports” set.

The “exclusive central pharmacy” element

• Multiple claims require prescription requests to be received only at the central pharmacy and all processing to be performed only by that central pharmacy.
• “Exclusive control” language appears in:
  • Claim 1: “exclusive central pharmacy” and “exclusive computer database associated with the exclusive central pharmacy”
  • Claim 2: database controlled exclusively by the exclusive central pharmacy

The “exclusive computer database” element

• Claims repeatedly require entry into an exclusive database and that prescriptions are processed using only the exclusive computer database.
• Claim 6 explicitly recites: use of the exclusive computer database is required for distribution.

Practical scope implication: systems that perform screening using a shared platform, a distributor system, a PBM network, or a database not exclusively controlled by the central pharmacy face higher non-infringement leverage.

The gating mechanics: abuse/detection result must determine shipping

• Claim 1: ship by courier/mail only if no potential abuse is found.
• Claim 3 and claim 4 add:
  • selectively blocking shipment (claim 3)
  • shipment blocked upon abuse association to a patient (claim 4)

The education and compliance workflow

• Claims require patient confirmation that educational material has been received and/or read prior to shipping/providing, at least for initial dispensing:
  • Claim 1: “prior to shipping”
  • Claim 9/12: “prior to providing … a first time” (claim 9) and “prior to providing … a first time” (claim 12)

Receipt confirmation and diversion reporting

• Patient receipt confirmation is required in all independent structures.
• Periodic reporting via the exclusive database to evaluate diversion patterns is explicit in claims 1 and 6, and in the GHB distribution variants.

What formulations or drug product types are covered by U.S. 7,895,059?

Answer: The claims are not formulation claims. They cover computerized distribution methods for prescription drugs, with explicit examples and dedicated dependent/independent coverage for gamma hydroxy butyrate (GHB).

What is explicitly recited

• “gamma hydroxy butyrate (GHB)” is explicitly claimed in:
  • claim 5 (dependent from claim 1)
  • claims 9, 10, 11, 12, 13

What is not claimed

• No direct chemical structure, salt form, polymorph, or manufacturing formulation parameters are claimed.
• Claim 13 includes a manufacturing step, but it is operationally tied to providing manufactured GHB only to the central pharmacy, not to composition/formulation.

How many claim sets are there and what do they map to in enforcement strategy?

Answer: The patent effectively has three enforcement “tracks”:

1. General centralized abuse-screened prescription distribution (claims 1, 2, 3, 4, 6, 14, and their dependents 15, 16).
2. GHB-specific centralized abuse-screened distribution (claims 9, 10, 11, 12).
3. GHB manufacturing-to-central pharmacy workflow plus centralized screening and gated distribution (claim 13).

Claim-by-claim scope map

When does U.S. Patent 7,895,059 lose exclusivity or expire?

Answer: No expiration date or priority data is provided in the prompt, so a definitive exclusivity/expiration timeline cannot be computed.

What patent estate surrounds U.S. 7,895,059: continuation, related methods, and likely overlapping claims?

Answer: No bibliographic data (application number, priority, continuation links, family members, assignee, or citing/cited documents) is provided in the prompt, so a complete landscape cannot be generated.

What “exclusive database” and “central pharmacy” features would generics or challengers attack in design-around?

Answer: The strongest likely design-around strategies follow from the literal claim structure:

Likely non-infringement levers

• Not using an “exclusive” database controlled by the central pharmacy (e.g., screening performed using a shared enterprise platform).
• Not processing “all prescriptions” only by the central pharmacy (e.g., distributed processing with decentralized dispensing decisions).
• Not gating shipment solely on database results tied to patient/prescriber abuse indicators.
• Not requiring education confirmation as a prerequisite to providing the drug.
• Avoiding patient receipt confirmation workflows as a required step.
• Omitting periodic diversion reporting as a claimed step (if required by the claim’s method execution).

Likely partial overlap areas (where infringement may still occur)

• Systems that replicate the education + credential eligibility + abuse detection gating + shipment restriction workflow may still infringe if they meet the “exclusive central pharmacy” and “exclusive database required” limitations.

What if the dispensing is routed through another pharmacy: how do claims 7-8 and 10-11 narrow scope?

Answer: The patent explicitly contemplates a scenario where the central pharmacy authorizes another pharmacy to dispense, but only if the other pharmacy applies specific controls from a defined set.

Claim 7 / Claim 10

• Central pharmacy authorizes another pharmacy to dispense.

Claim 8 / Claim 11: other-pharmacy controls list

The dependent claims specify a control selection group including:

• Confirm with the patient educational material received and/or read
• Confirm receipt of the drug
• Contact the patient’s insurance company
• Question early refill requests
• Flag repeat lost/stolen/destroyed/spilled prescriptions
• Flag patient paid cash
• Flag early refill requests
• Limit prescription to limited duration supply

Scope implication: routing through another pharmacy is not a safe harbor; the claims require a control implementation set to be selected and used.

How does claim 13 extend the reach upstream into manufacturing and supply chain?

Answer: Claim 13 adds manufacturing and “only provide to central pharmacy” constraints:

• Manufacture GHB
• Provide manufactured GHB only to the exclusive central pharmacy
• Then execute the full centralized distribution method

Infringement focus: upstream logistics and controlled supply chain configuration, not only the distribution IT workflow.

What Orange Book status or FDA pathway considerations apply to this patent?

Answer: No FDA listing/pathway information is provided in the prompt, so Orange Book or regulatory status cannot be mapped to this patent.

Key Takeaways

• U.S. Patent 7,895,059 protects computer-implemented centralized distribution workflows for prescription drugs, with explicit coverage for GHB.
• The claims are defined by a tight technical-operational nexus: exclusive central pharmacy, exclusive computer database, mandatory database-driven processing, prescriber credential eligibility checks, patient education confirmation, abuse/diversion screening, conditional shipment (mail/courier), patient receipt confirmation, and periodic diversion reporting.
• Scope expands in GHB-specific and upstream variants:
  • GHB distribution adds GHB educational material and GHB abuse framing.
  • Claim 13 adds manufacturing-to-exclusive-central-pharmacy-only supply.
• Dispensing through another pharmacy is contemplated only with dependent-claim control measures (education/receipt confirmation, payer and refill scrutiny, lost/stolen flags, cash-payment flags, and limited-duration supply).

FAQs

1. Does U.S. Patent 7,895,059 claim drug formulation or composition?
   No. It claims computerized distribution/dispensing methods, with manufacturing referenced operationally in claim 13 for GHB supply to the central pharmacy.

2. Is GHB the only drug covered?
   No. General prescription drug claims exist (e.g., claim 1, claim 6, claim 14) that also include a dependent GHB limitation (claim 5), plus dedicated GHB independent claims (claims 9, 12, 13).

3. What is the biggest design-around risk in implementing a similar program?
   Meeting the “exclusive central pharmacy” and “exclusive computer database required for distribution” limitations while ensuring all processing is performed using only that exclusive database.

4. Do the dependent claims require all listed controls when another pharmacy dispenses?
   The dependent claims describe controls selected from a listed group; each claim’s wording frames controls as selected from that set rather than automatically requiring every item.

5. Does claim 13 require the method to include manufacturing?
   Yes. Claim 13 explicitly includes manufacturing GHB and providing manufactured GHB only to the exclusive central pharmacy before performing the centralized database screening and shipment steps.

References

1. Provided claims text for U.S. Patent 7,895,059 (user-supplied).